Dear Alphastox Subscribers,
What a great week two weeks it has been for Alphastox subscribers and iCo Therapeutics (ICO) shareholders. We first notified our subscribers about this great opportunity on December 12th, 2012 when iCo was sitting at $0.65. Today, just two weeks later, iCo hits a year-high $0.86! That’s over a 32% return in just two weeks! And not only that, but iCo trades with heavy volume- trading an average of 380,000 shares a day since we sent out our report.
Andrew Rae, iCo’s CEO, has been marketing in Europe and speaking with different pharmaceutical firms in London and Paris. This is a very good sign before iCo releases their interim data results from their Phase II trial. From what we have been hearing, Andrew should be releasing a corporate update before he heads to the Biotech conference in San Francisco on January 7th. This is a great company, with an experienced and successful management team who know how to take a small junior to the next level. They have the right partners in place with Isis Pharmaceuticals and are well structured with having the Juvenile Diabetes Research Foundation funding 40% of their Phase II trial.
This is a story we continue to believe in and will continue to support it in the market. Everyone needs to keep iCo Therapeutics (ICO) on watch before they release their interim data II results. iCo is looking for a regional partnership on their 007 asset and/or some sort of a transaction that will push this stock to new heights. These results will be a major catalyst for shareholders. Never forget what fund manager Hugh Cleland of BluMont Capital said on iCo “I have deep familiarity with macular degeneration due to my participation in the $0.20 unit financing for iCo Therapeutics (ICO:CVE) in November 2011. Diabetic macular edema (DME) is the lead indication for iCo. My advisory board was very enthusiastic about iCo for a variety of reasons, and the $0.20 unit, which was led by management and board members, has worked out very well, with the stock now trading good volume at around CA$0.70. If the phase 2 DME trials go the way we think they will, the stock should go significantly higher, likely into the $2–4 range. But it is not without risk.”
With the junior mining and oil and gas sector taking a big hit in 2012, iCo is looking like it has the potential to be one of the biggest gainers on the TSX Venture Exchange from 2012-2013.